Argipressin

Phase 3Small molecule

KKristina Svennerholm

Argipressin is one of 4 small molecule programs targeting Intensive Care. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intensive CareNot yet recruiting

Intensive CarePhase 3

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Intensive Care

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

1 2

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Phase 3

1 3

Dexamethasone IV

MMayo Clinic

Phase 3

1 4

Argipressin

KKristina Svennerholm

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Not yet recruiting

Intensive Care

NCT07063680

Clinical

Trials by Indication[1]

Intensive Care1 trial

Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock

Not yet recruiting·—·Phase 3·NCT07063680·390 enrolled

Blood Loss1 trial

Argipressin's Influence on Blood Loss During Hepatic Resection

Completed·KKristina Svennerholm·Phase 4·NCT05293041·248 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Argipressin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Argipressin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Argipressin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kristina Svennerholm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKristina Svennerholm

Argipressin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Intensive Care1 trial

Blood Loss1 trial

References

Drug Info

Quick Facts

Related News